The Influence of Visceral Adiposity on Overall Survival: Exploring "Obesity Paradox" Among Hepatocellular Carcinoma Patients Who Receiving Immunotherapy

被引:1
作者
Zhou, Yanzhao [1 ]
Ouyang, Jingzhong [2 ,3 ,4 ,5 ]
Yang, Hongcai [6 ]
Wang, Zhengzheng [2 ,3 ]
Yang, Yi [4 ,5 ]
Li, Qingjun [2 ,3 ]
Zhao, Haitao [7 ]
Zhou, Jinxue [2 ,3 ]
Li, Qiang [1 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Liver Canc Res Ctr, Natl Clin Res Ctr Canc,Dept Hepatobiliary Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China
[2] Zhengzhou Univ, Canc Hosp, Dept Hepatobiliary & Pancreat Surg, Zhengzhou 450008, Henan, Peoples R China
[3] Henan Canc Hosp, Zhengzhou 450008, Henan, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Dept Hepatobiliary Surg,Canc Hosp, Beijing, Peoples R China
[5] Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Gene Editing Screening & Res & Dev R&D Dig, Beijing, Peoples R China
[6] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Intervent Therapy, Natl Clin Res Ctr Canc,Cancer Hosp, Beijing, Peoples R China
[7] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Liver Surg, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatocellular carcinoma; immunotherapy; body mass index; body composition; obesity paradox; LUNG-CANCER; ASSOCIATION; OUTCOMES; THERAPY; MASS; FAT;
D O I
10.2147/JHC.S453262
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The impact of visceral adiposity on overall survival (OS) in hepatocellular carcinoma (HCC) receiving immunotherapy was unclear. We aimed to determine how visceral adiposity affected OS and explore the interrelationships between visceral adiposity, body mass index (BMI), and other body compositions. Patients and Methods: Data from three centers were retrospectively analyzed. Skeletal muscle index (SMI), skeletal muscle density (SMD), visceral adipose tissue index (VATI), and subcutaneous adipose tissue index (SATI) were used to define each body composition. The BMI subgroups included the underweight, the normal weight, and the obesity. The Log rank test compared survival curves calculated by the Kaplan -Meier method. The relationships between body compositions and BMI with OS were examined using Cox proportional risk regression models. Results: A total of 305 patients who met the criteria were included. Patients with low VATI had significantly worse OS ( P = 0.001). The protections of VATI ( P = 0.011) on OS were independent of covariates. However, after additional adjustment of SMI, the effect of VATI on OS disappeared ( P = 0.146), but the effect of SMD on OS did not ( P = 0.021). BMI has a significant U-shaped relationship with OS, and the effect of BMI on OS equally disappeared after additional adjustment by SMI. Conclusion: This study first demonstrated that high VATI and mid -level BMI were protective for the survival of patients with HCC receiving immunotherapy. Skeletal muscle status (including SMI and SMD) may be the better predictor for outcomes of patients with HCC receiving immunotherapy.
引用
收藏
页码:1193 / 1206
页数:14
相关论文
共 33 条
[1]   Obesity and cancer risk: Emerging biological mechanisms and perspectives [J].
Avgerinos, Konstantinos, I ;
Spyrou, Nikolaos ;
Mantzoros, Christos S. ;
Dalamaga, Maria .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 92 :121-135
[2]   Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer [J].
Barbi, Joseph ;
Patnaik, Santosh K. ;
Pabla, Sarabjot ;
Zollo, Robert ;
Smith, Randall J., Jr. ;
Sass, Stephanie N. ;
Srinivasan, Aravind ;
Petrucci, Cara ;
Seager, Robert ;
Conroy, Jeffrey ;
Kannisto, Eric ;
Wang, Xialong ;
Shah, Shrunjal ;
Gosain, Rohit ;
Attwood, Kris ;
Roche, Charles ;
Yendamuri, Sai .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (08) :1333-1348
[3]   The diverse roles of adiponectin in non-small-cell lung cancer: current data and future perspectives [J].
Boura, Paraskevi ;
Loukides, Stylianos ;
Grapsa, Dimitra ;
Achimastos, Apostolos ;
Syrigos, Konstantinos .
FUTURE ONCOLOGY, 2015, 11 (15) :2193-2203
[4]   Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma [J].
Chen, Bang-Bin ;
Liang, Po-Chin ;
Shih, Tiffany Ting-Fang ;
Liu, Tsung-Hao ;
Shen, Ying-Chun ;
Lu, Li-Chun ;
Lin, Zhong-Zhe ;
Hsu, Chiun ;
Hsu, Chih-Hung ;
Cheng, Ann-Lii ;
Shao, Yu-Yun .
EUROPEAN RADIOLOGY, 2023, 33 (01) :512-522
[5]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[6]  
European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
[7]   Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes [J].
Fang, Shenying ;
Wang, Yuling ;
Dang, Yifang ;
Gagel, Andrew ;
Ross, Merrick I. ;
Gershenwald, Jeffrey E. ;
Cormier, Janice N. ;
Wargo, Jennifer ;
Haydu, Lauren E. ;
Davies, Michael A. ;
McQuade, Jennifer L. ;
Sui, Dawen ;
Bassett, Roland L. ;
Reveille, John D. ;
Wei, Qingyi ;
Amos, Christopher I. ;
Lee, Jeffrey E. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (08) :1792-1795
[8]   Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma [J].
Finn, Richard S. ;
Ikeda, Masafumi ;
Zhu, Andrew X. ;
Sung, Max W. ;
Baron, Ari D. ;
Kudo, Masatoshi ;
Okusaka, Takuji ;
Kobayashi, Masahiro ;
Kumada, Hiromitsu ;
Kaneko, Shuichi ;
Pracht, Marc ;
Mamontov, Konstantin ;
Meyer, Tim ;
Kubota, Tomoki ;
Dutcus, Corina E. ;
Saito, Kenichi ;
Siegel, Abby B. ;
Dubrovsky, Leonid ;
Mody, Kalgi ;
Llovet, Josep M. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (26) :2960-+
[9]   Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].
Finn, Richard S. ;
Qin, Shukui ;
Ikeda, Masafumi ;
Galle, Peter R. ;
Ducreux, Michel ;
Kim, Tae-You ;
Kudo, Masatoshi ;
Breder, Valeriy ;
Merle, Philippe ;
Kaseb, Ahmed O. ;
Li, Daneng ;
Verret, Wendy ;
Xu, Derek-Zhen ;
Hernandez, Sairy ;
Liu, Juan ;
Huang, Chen ;
Mulla, Sohail ;
Wang, Yulei ;
Lim, Ho Yeong ;
Zhu, Andrew X. ;
Cheng, Ann-Lii .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905
[10]   Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial [J].
Finn, Richard S. ;
Ryoo, Baek-Yeol ;
Merle, Philippe ;
Kudo, Masatoshi ;
Bouattour, Mohamed ;
Lim, Ho Yeong ;
Breder, Valeriy ;
Edeline, Julien ;
Chao, Yee ;
Ogasawara, Sadahisa ;
Yau, Thomas ;
Garrido, Marcelo ;
Chan, Stephen L. ;
Knox, Jennifer ;
Daniele, Bruno ;
Ebbinghaus, Scot W. ;
Chen, Erluo ;
Siegel, Abby B. ;
Zhu, Andrew X. ;
Cheng, Ann-Lii .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (03) :193-+